Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. The lead program features innovative antibody design as well as state of the art linker and payload technology to target Nectin-4 – an important and validated target for a broad range of cancers.
Year of investment
2021
Sector
Drug development
Location
Duisburg, Germany
Website
http://emergencetx.com/